Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bipolar Disorder in Epilepsy

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT00365482
First received: August 15, 2006
Last updated: May 15, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to find out how often major mood swings occur in patients treated in a specialty epilepsy center.


Condition
Epilepsy
Bipolar Disorder

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Bipolar Disorder in Epilepsy

Resource links provided by NLM:


Further study details as provided by North Shore Long Island Jewish Health System:

Enrollment: 102
Study Start Date: August 2006
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Detailed Description:

Bipolar disorder (a condition of major mood swings) or milder forms of ups and downs in mood may occur with a number to neurological conditions. Recently, one study showed that these mood changes occur fairly often in individuals with epilepsy studied in the general community. We speculate that bipolar symptoms occur with even higher frequency in a tertiary epilepsy center than that encountered in the previous community-based study. The goals of this study are to assess:

  • the rate of bipolar symptoms as measured by a self-reporting screening tool in a tertiary epilepsy center setting
  • the meaning of a positive screening score in epilepsy patients
  • the utility, sensitivity and specificity of alternative screening tools for mood instability in epilepsy patients
  • the correlation of mood instability with seizure-related variables
  • the relation of a positive screening score on quality of life.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Epilepsy patients at the Long Island Jewish Comprehensive Epilepsy Center

Criteria

Inclusion Criteria:

  • Male or female 18 years of age or older
  • Being evaluated at the Long Island Jewish Comprehensive Epilepsy Center
  • Capable of completing self-reporting questionnaires

Exclusion Criteria:

  • Patients with mental retardation
  • Patients with pseudoseizures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00365482

Locations
United States, New York
North Shore Long Island Jewish Health System
Great Neck, New York, United States, 11021
Sponsors and Collaborators
North Shore Long Island Jewish Health System
GlaxoSmithKline
Investigators
Principal Investigator: Sean Hwang, MD Long Island Jewish Medical Center
  More Information

No publications provided

Responsible Party: North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier: NCT00365482     History of Changes
Other Study ID Numbers: 06.02.029
Study First Received: August 15, 2006
Last Updated: May 15, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by North Shore Long Island Jewish Health System:
Epilepsy
Bipolar Disorder

Additional relevant MeSH terms:
Bipolar Disorder
Disease
Epilepsy
Affective Disorders, Psychotic
Brain Diseases
Central Nervous System Diseases
Mental Disorders
Mood Disorders
Nervous System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on November 23, 2014